Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07717164 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PRAISE-IR Versus CIBMTR Controls

StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 28, 2026 (before its estimated September 20, 2026 completion). Its status may not reflect the trial's current state.
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Miltenyi Biomedicine GmbH

Record History

  1. Primary endpoint(s) modified Secondary endpoints: 1 to 7 · Study title shortened, about 31 wordsv2 Show 2 more changesShow less
    • Secondary endpoints: 1 to 7
    • Study title shortened, about 31 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The rationale to conduct this RWE study is to provide data to support the safety of CD34 selected grafts versus T replete PBSC transplants to address concerns about increased TRM in CD34 selected graft recipients.
Trial Details
NCT Number NCT07717164
Lead Sponsor Miltenyi Biomedicine GmbH
Conditions ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome)
Enrollment 51 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov